EGFR and brain neoplasm: In this preclinical study, U251 cells were specifically chosen, from in vitro immunofluorescence assays, to establish the orthotopic brain tumor model in order to assess the imaging performance of panitumumab-IRDye800 in a challenging yet realistic environment where EGFR expression in tumors is more modest.